Biotech
Science with the potential to change human health. New approaches to unmet medical needs.
Life sciences / TherapeuticsCapital for
what comes next.
We pursue distinctive opportunities across Biotech, TMT, FinTech, Infrastructure, and Consumer Products.
Explore our focusPerspective
Independent
Focus
Five core investment sectors
Approach
Conviction & connection
Structure
Deal-specific SPVs
01 / StrategyOur investment focus
Big ideas.
Lasting relevance.
From advances in human health to the systems that connect our world, we focus on sectors shaping how people live, work, and build.
TMT
Technology, media, and telecommunications. The platforms changing how we create and connect.
Technology / Media / TelecomFinTech
Better ways to move, access, and manage capital. Financial services built for a changing economy.
Financial technologyInfrastructure
The essential systems behind everyday life. Physical and digital foundations for future growth.
Physical / Digital infrastructureConsumer Products
Everyday brands and essentials. Skincare, fragrances, nutraceuticals, clothing and accessories, and household products.
Beauty / Wellness / Lifestyle / Home
Headquarters
Nashville, Tennessee.
02 / ManagementThe person behind the perspective
Caleb UpkinsNashville, TN
Managing Partner
Caleb Upkins
Bringing an operator’s perspective to private capital.
Caleb leads Colibri Capital from Nashville. His background spans technology, product marketing, and connecting private capital with operating companies.
Before co-founding UPK Partners, Caleb worked in global growth product marketing at YouTube. He earned his bachelor’s degree at the Wharton School of the University of Pennsylvania.
At Colibri, his focus brings together an interest in mental health and a broader perspective across technology, financial innovation, infrastructure, and consumer products.
Connect with Caleb on LinkedIn, opens in a new tab03 / Investment focusBiotech
A focus on
human health.
CAD Therapeutics, Inc. is a proposed investment for our first special purpose vehicle.
01 / CAD Therapeutics, Inc.A new perspective
Proposed investment — not closedThe proposed investment in CAD Therapeutics, Inc. has not closed and is not a completed portfolio holding. There is no assurance that the investment will be completed.
A new perspective
on mental health.
CAD Therapeutics is an FDA Phase III trial candidate developing an investigational approach to post-traumatic stress disorder (PTSD) and VMS (Hot Flashes).
Its product candidate is investigational and is not FDA-approved. Safety and efficacy have not been established.
Visit company website opens in a new tab04 / ContactColibri Capital LLC
Good things start
with a conversation.
For general inquiries and introductions, connect with Caleb.
Let’s connect by emailcaleb@colibricapitalgp.com
Caleb Upkins
Managing Partner
Nashville, Tennessee